1. Sortica VA, Fiegenbaum M, Lima LO, Van der Sand CR, Van der Sand LC, Ferreira ME, et al.
SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians. Clin Chem Lab Med. 2012; 50:441–448. PMID:
22505549.
Article
2. Zhang P, Wang M, Zhang H, Wang Q. Effects of statins on rat liver microsomal aspirin esterase activities in vitro. Lat Am J Pharm. 2013; 32:1501–1507.
3. Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lütjohann D, et al. Impact of the
SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther. 2006; 79:419–426. PMID:
16678544.
4. Hedman M, Antikainen M, Holmberg C, Neuvonen M, Eichelbaum M, Kivistö KT, et al. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the
SLCO1B1 and
ABCB1 genes. Br J Clin Pharmacol. 2006; 61:706–715. PMID:
16722833.
5. Fu Q, Li YP, Gao Y, Yang SH, Lu PQ, Jia M, et al. Lack of association between
SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals. Eur J Clin Pharmacol. 2013; 69:1269–1274. PMID:
23263738.
6. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of
SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007; 82:726–733. PMID:
17473846.
7. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M.
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006; 16:873–879. PMID:
17108811.
8. Zhang W, Chen BL, Ozdemir V, He YJ, Zhou G, Peng DD, et al.
SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br J Clin Pharmacol. 2007; 64:346–352. PMID:
17439540.
9. Tachibana-Iimori R, Tabara Y, Kusuhara H, Kohara K, Kawamoto R, Nakura J, et al. Effect of genetic polymorphism of OATP-C (
SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet. 2004; 19:375–380. PMID:
15548849.
10. Yang GP, Yuan H, Tang B, Zhang W, Wang LS, Huang ZJ, et al. Lack of effect of genetic polymorphisms of
SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients. Acta Pharmacol Sin. 2010; 31:382–386. PMID:
20140004.
11. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25:603–605. PMID:
20652370.
Article
12. Bailey KM, Romaine SP, Jackson BM, Farrin AJ, Efthymiou M, Barth JH, et al. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. Circ Cardiovasc Genet. 2010; 3:276–285. PMID:
20207952.
13. Couvert P, Giral P, Dejager S, Gu J, Huby T, Chapman MJ, et al. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics. 2008; 9:1217–1227. PMID:
18781850.
Article
14. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998; 17:2815–2834. PMID:
9921604.
Article